Introduction
============

Cancer burden is expected to show a rapid growth with the aging population and increasing cancer incidence \[[@b1-crt-2014-001]-[@b6-crt-2014-001]\]. The share of elders (or those aged 65 years or older) in the United States increased from 10.0% in 1972 to 12.7% in 2008, whereas the share for South Korea (Korea hereafter) registered a similar but steeper trend, i.e., 7.3% in 2000 to 11.1% in 2010 \[[@b1-crt-2014-001]\]. America's age-standardized incidence rate per 100,000 for all cancers rose from 400 in 1975 to 472 in 2004 \[[@b2-crt-2014-001]\], while the statistic for Korea went up from 205 in 2000 to 286 in 2010 \[[@b3-crt-2014-001]\]. As a result, the share of direct cost for cancer care in the United States economy doubled from 0.32% in 1972 to 0.66% in 2008 \[[@b1-crt-2014-001],[@b4-crt-2014-001],[@b5-crt-2014-001]\]. Likewise, the population-health burden of cancer in Korea (disability-adjusted life years per 100,000) showed a rapid growth from 1,109 person-years in 2000 to 1,681 person-years in 2010 \[[@b6-crt-2014-001]\]. As cancer burden increases rapidly, a burden-of-cancer study designed to improve the quality of patient life and to set up national priorities for resource allocation in health services becomes more essential.

Based on previous studies, a large part of cancer burden in an advanced nation comes from breast, colon, lung, and prostate cancers \[[@b7-crt-2014-001]-[@b9-crt-2014-001]\]. In terms of direct cost (national dollars, million), these cancers ranked in the top four in the United States for 1996 (5,980, 5,710, 4,680, and 4,610) \[[@b7-crt-2014-001]\], Canada for 1998 (120, 216, 228, and 103) \[[@b8-crt-2014-001]\] and New South Wales in Australia for 2004 (77, 132, 77, and 121) \[[@b9-crt-2014-001]\]. Other research has shown that as medical technology advanced and cancer survival increased, the share of income loss from premature death in cancer burden gradually fell in the developed world \[[@b4-crt-2014-001]-[@b5-crt-2014-001],[@b7-crt-2014-001],[@b10-crt-2014-001]-[@b13-crt-2014-001]\]. The share in the United States, which was 73% in 1972 \[[@b4-crt-2014-001]\], decreased to 61% in 1990 \[[@b7-crt-2014-001]\], dipping further to 51% in 2008 \[[@b5-crt-2014-001]\]. Likewise, the number in Sweden went down from 45% in 2000 to 39% in 2004 \[[@b10-crt-2014-001]\]. However, based on recent reviews, most existing literature on national economic burden has been limited to direct medical cost and comprehensive examination on national economic burden by cancer site, gender, age group, and cost component over a long time span has been limited \[[@b10-crt-2014-001],[@b11-crt-2014-001]\].

Some researchers have estimated economic burden for major cancers in Korea for 2002 and 2005 \[[@b12-crt-2014-001],[@b13-crt-2014-001]\]. According to their findings, liver, stomach, and lung cancers led the nation's cancer burden, with the costs of 1,749, 1,784, and 1,289 million US\$ in 2002 and 2,387, 2,321, and 1,614 million US\$ in 2005, respectively (or the shares of 18.6%, 18.9%, and 13.7% in all cancers for 2002 and 17.4%, 16.9%, and 11.7% for 2005, respectively) \[[@b12-crt-2014-001],[@b13-crt-2014-001]\]. However, cancers that are prevalent in other developed nations, including breast, colon, and prostate cancers, are becoming more common in Korea, a nation characterized by rapid westernization in health behavior in the past two decades \[[@b3-crt-2014-001]\]. In addition, Korea is becoming an aging society populated by one of the greatest proportions of elderly by 2020 \[[@b14-crt-2014-001]\]. With such significant transitions, updating the estimation of economic burden for major cancers in Korea during the period 2000-2010 will not only provide invaluable opportunities for designing the nation's healthcare policies for the future, but will also be helpful in establishing the direction of future study for other nations with similar transformations. In this vein, this research involves a comprehensive examination of cancer burden in Korea during 2000-2010, i.e., by cancer site, gender, age group, and cost component.

Materials and Methods
=====================

This study uses the cost of illness (COI) method \[[@b7-crt-2014-001]-[@b9-crt-2014-001],[@b12-crt-2014-001],[@b13-crt-2014-001]\] to estimate the economic burden of cancer in Korea during 2000-2010 by cancer site, gender, and age group. Based on the COI classification, the economic burden of disease consists of three components, i.e., direct, morbidity, and mortality cost. Direct cost is "expenditure for medical services associated with the treatment and care of the disease entity" whereas (indirect) morbidity/mortality cost is "productivity loss due to disability/premature death associated with the disease entity" \[[@b7-crt-2014-001]\].

[Table 1](#t1-crt-2014-001){ref-type="table"} shows components, formulas, and data sources for the economic burden of cancer in Korea during 2000-2010. Direct cost includes medical cost covered by health insurance, medical cost uncovered, transportation cost, caregiver cost and cost for alternative medicine. Data on medical cost (covered for hospitalization, outpatient visit, and drug prescription) came from national health insurance claims data \[[@b15-crt-2014-001]\] (the most representative health data in Korea given that the Korean government launched a compulsory national health insurance program for the entire population in Y1989 \[[@b12-crt-2014-001]\]). Medical cost uncovered was derived from national surveys on out-of-pocket expenditure of patients enrolled in health insurance \[[@b16-crt-2014-001]\]. For calculation of transportation cost, the number of outpatient visit days \[[@b15-crt-2014-001]\] was multiplied by transportation cost per outpatient visit day (4.9 US\$ \[or \$4.9 hereafter\] in 2002 \[[@b12-crt-2014-001]\] before being adjusted for inflation \[[@b17-crt-2014-001]\]). This value was multiplied by 2 (with an assumption that a family member would be present for each outpatient visit \[[@b12-crt-2014-001]\]). For the estimation of caregiver cost, its "inpatient" and "outpatient" parts were calculated and then combined. Regarding the former part, the number of inpatient days \[[@b15-crt-2014-001]\] was multiplied by caregiver cost per inpatient day (\$50 in 2002 \[[@b12-crt-2014-001]\] before being adjusted for inflation \[[@b17-crt-2014-001]\]). Regarding the latter part, the number of outpatient visit days \[[@b15-crt-2014-001]\] was multiplied by 4 (the number of hours per outpatient visit) \[[@b12-crt-2014-001]\] and caregiver cost per outpatient visit hour (\$9.3 in 2002 \[[@b12-crt-2014-001]\] before being adjusted for inflation \[[@b17-crt-2014-001]\]). For calculation of cost for alternative medicine, the number of patients \[[@b15-crt-2014-001]\] was multiplied by cost for alternative medicine per patient (\$1,150 in 2002 \[[@b12-crt-2014-001]\] before being adjusted for inflation \[[@b17-crt-2014-001]\]) ([Table 1](#t1-crt-2014-001){ref-type="table"}).

Morbidity and mortality costs were derived based on a human capital approach, which assumes that the monetary value of productivity loss equals the current wage \[[@b7-crt-2014-001]-[@b9-crt-2014-001],[@b12-crt-2014-001],[@b13-crt-2014-001],[@b18-crt-2014-001]\]. It was assumed that those younger than 15 or older than 69 did not work \[[@b12-crt-2014-001],[@b13-crt-2014-001]\]. For calculation of morbidity cost, productivity loss due to cancer-specific disability "inside" and "outside" the labor market were estimated and then combined. Regarding the former loss, the yearly wage (or productivity loss) \[[@b17-crt-2014-001]\] was multiplied by the number of patients \[[@b15-crt-2014-001]\], the participation rate for economic activity \[[@b17-crt-2014-001]\], the employment rate \[[@b17-crt-2014-001]\], and the rate of job loss for the cancer patient (0.51) \[[@b13-crt-2014-001]\] (the participation rate for economic activity and the employment rate vary by gender, age group, and year). Regarding the latter loss, women's yearly wage (or productivity loss) \[[@b17-crt-2014-001]\] was multiplied by the number of female patients \[[@b15-crt-2014-001]\], women's non-participation rate for economic activity \[[@b17-crt-2014-001]\], women's participation rate for housework (0.67) \[[@b13-crt-2014-001]\], and the rate of housework loss for the female cancer patient (86.5 days/365.0 days) \[[@b13-crt-2014-001]\] (The women's non-participation rate for economic activity varies by age group and year). Likewise, for calculation of mortality cost, productivity loss due to cancer-specific premature death "inside" and " outside" the labor market were estimated and then combined. Regarding the former loss, the number of mortalities \[[@b17-crt-2014-001]\] was multiplied by the expected value of the future income during potential years of life lost \[[@b17-crt-2014-001]\] with a discount rate (0.03) \[[@b13-crt-2014-001]\]. Regarding the latter loss, the number of women's mortalities \[[@b17-crt-2014-001]\] was multiplied by the expected value of women's opportunity cost (for housework) during potential years of life lost \[[@b13-crt-2014-001],[@b17-crt-2014-001]\] with a discount rate (0.03) \[[@b13-crt-2014-001]\]. For calculation of the expected value of the future income or women's opportunity cost for housework during potential years of life lost from a base year (e.g., 2010), it was assumed that (1) the participation rate for economic activity and the employment rate (varying by gender and age group in a given year) stay the same in the future as in the base year and (2) the women's non-participation rate for economic activity (varying by age group in a given year) remains the same in the future as in the base year.

Results
=======

[Tables 2](#t2-crt-2014-001){ref-type="table"} and [3](#t3-crt-2014-001){ref-type="table"} shows the number of patients (or mortalities) in Korea by cancer site and gender in 2000 and 2010, listed based on the rank in 2010. The total number of cancer patients increased by 66.67%, from 544,402 to 907,347 during 2000-2010. The increase in cancer prevalence during the period was more pronounced for women than for men, with the growth rate of 79.1% versus 54.5% (from 270,208 to 483,813 vs. from 274,194 to 423,534). Thyroid, breast, and prostate cancers led this rapid growth of prevalence during the period. For example, the rank/number of prevalence increased from the 5th/45,619 to the 1st/196,490 for thyroid cancer, from the 6th/42,605 to the 4th/97,507 for breast cancer, and from the 14th/9,881 to the 7th/36,105 for prostate cancer. It is also noteworthy that kidney and bladder cancers entered the top ten during the period, i.e., the 15th/9,855 and the 12th/11,674 in 2000 to the 8th/28,582 and the 10th/21,086 in 2010, respectively. On the contrary, the ranks/numbers of prevalence for liver cancer, non-Hodgkin lymphoma, and ovary cancer declined during the period, i.e., the 3rd/57,161, the 8th/17,261, and the 9th/16,403 in 2000 to the 6th/53,808, the 11th/16,571, and the 12th/14,542 in 2010, respectively. [Table 4](#t4-crt-2014-001){ref-type="table"} and [Fig. 1](#f1-crt-2014-001){ref-type="fig"} describe economic burden in Korea by cancer site and gender during 2000-2010 (with the shares of mortality cost in parentheses for the table). In terms of the total burden for the total population (million \$), liver, stomach, and lung cancers ranked 1st (3,114), 2nd (3,046), and 4th (1,988) in 2010 after holding the same positions in 2000 (2,065, 2,036, and 1,202). Colorectal cancer, a top five (837) in 2000, replaced leukemia as a top three in 2010 (2,210). Thyroid cancer, out of the top ten in 2000 (11th, 257), made the top five in 2010 (1,724). Likewise, breast cancer, a top seven (529) in 2000, became a top six (1,659) in 2010. A similar trend was observed for men. In terms of the total burden, liver, stomach, and lung cancers constituted the top three both in 2000 (1,744, 1,332, and 881) and in 2010 (2,638, 2,090, and 1,476). Colorectal cancer and leukemia, which ranked 5th (525) and 4th (790) in 2000, switched their positions in 2010 (4th, 1,420 vs. 5th, 965). Thyroid cancer, out of the top ten in 2000 (13th, 110), joined the top six in 2010 (707) ([Tables 2](#t2-crt-2014-001){ref-type="table"}-[4](#t4-crt-2014-001){ref-type="table"}) ([Fig. 1](#f1-crt-2014-001){ref-type="fig"}).

Some gender differences can be seen in [Table 4](#t4-crt-2014-001){ref-type="table"}, as breast and thyroid cancers made the top two instead of liver and stomach cancers for women's total burden in 2010 (1,648, 1,017 vs. 477, 956). Economic burden in Korea by cancer site and age group in 2000 and 2010 is described in [Table 5](#t5-crt-2014-001){ref-type="table"}. For the age group 0-14 years old, leukemia, brain cancer, and non-Hodgkin lymphoma led the total burden during 2000-2010. For those aged 15 years or older, liver, stomach, colorectal, and lung cancers constituted the top four in both 2000 and in 2010. However, the former two were more dominant for the age group 15-69 years old, while the latter two were more significant for those aged 70 years or older. Indeed, the rise of colorectal cancer was more evident for the older age group and the opposite was true for thyroid cancer. Finally, [Table 6](#t6-crt-2014-001){ref-type="table"} and [Fig. 2](#f2-crt-2014-001){ref-type="fig"} show the economic burden of cancer in Korea by cost component during 2000-2010. With an average annual growth rate of 8.9%, the total burden (million \$) increased from 11,424 to 20,858 during the period. The share of mortality cost in the total burden dropped from 70.7% to 51.7% during 2000-2010, as the figures for most cancers fell by more than 10.0% during the period ([Table 4](#t4-crt-2014-001){ref-type="table"}, [Fig. 1](#f1-crt-2014-001){ref-type="fig"}). On the contrary, the shares of direct and morbidity cost in the total burden rose during 2000-2010, from 5.6% to 14.7% for medical cost (covered), from 2.9% to 3.8% for medical cost (uncovered), from 0.2% to 0.4% for transportation cost, from 2.5% to 4.4% for caregiver cost, from 5.4% to 6.7% for the cost of alternative medicine, and from 12.8% to 18.3% for morbidity cost. Colorectal, thyroid, breast, and prostate cancers led this rapid growth of direct and morbidity cost during the period ([Table 4](#t4-crt-2014-001){ref-type="table"}, [Fig. 1](#f1-crt-2014-001){ref-type="fig"}). For example, the rank/amount of direct cost (million \$) increased from the 4th/211 to the 1st/855 for colorectal cancer, from the 6th/120 to the 3rd/703 for thyroid cancer, from the 5th/131 to the 4th/673 for breast cancer, and from the 18th/26 to the 8th/194 for prostate cancer (data not reported in the tables) ([Tables 5](#t5-crt-2014-001){ref-type="table"} and [6](#t6-crt-2014-001){ref-type="table"}, [Fig. 2](#f2-crt-2014-001){ref-type="fig"}).

Discussion
==========

1. Main findings of this study
------------------------------

Colorectal, thyroid, and breast cancers became more significant in terms of economic burden for Korea during 2000-2010. The rise of colorectal cancer was more evident for the older age group and the opposite was true for thyroid cancer. In addition, liver and stomach cancers were prominent in the nation during the period. Finally, the share of mortality cost in the total burden dropped from 71% to 51% in Korea during 2000-2010, and the relative growths of direct and morbidity cost were led by colorectal, thyroid, breast, and prostate cancers during the period. These results show that the economic burden of cancer in Korea is characterized by an increasing importance of chronic components.

2. What is already known on this topic
--------------------------------------

The economic burden of cancer in an advanced nation centers on breast, colon, lung, and prostate cancers. Indeed, as medical technology advances and cancer survival increases, the share of mortality cost in cancer burden registers a graduate fall in the developed world.

3. What this study adds
-----------------------

This research presents a very rare analysis of economic burden by cancer site, gender, age group, and cost component in Korea during 2000-2010. Most existing literature on national economic burden has been limited to direct medical cost, and comprehensive examination of the national economic burden by cancer site, gender, age group, and cost component over a long time span has been limited.

This research shows that Korea is converging with other advanced nations in the economic burden of cancer. In terms of direct cost, breast, colon, lung and prostate cancers, which ranked in the top four in the United States for 1996, Canada for 1998 and New South Wales in Australia for 2004, constituted the top eight in Korea for 2010, i.e., colorectal cancer (first position, 855 million US\$), breast cancer (fourth, 673 million US\$), lung cancer (fifth, 651 million US\$) and prostate cancer (eighth, 194 million US\$). In addition, the share of mortality cost in the total burden, which dropped from 73% to 51% in the United States during 1972-2008, registered a similar trend in Korea, i.e., a fall from 71% to 51%, albeit during a much shorter period, 2000-2010. Korea's convergence with other advanced nations in cancer burden might reflect their convergence in living standards, the age structure, health behavior and medical technology during the past four decades. The rise of Korea's Gross Domestic Product per capita relative to the Organisation for Economic Cooperation and Development average (e.g., from 0.26 to 0.77 during 1980-2012 in terms of Purchasing Power Parity current international dollars \[[@b1-crt-2014-001]\]) has been accompanied by the growing proportion of the elderly population and the rise of meat consumption. Korea's share of the population aged 60 years or older, which was 15% in 2009, is likely to reach 21% in 2018, the figure for the developed regions in 2009 \[[@b14-crt-2014-001],[@b17-crt-2014-001]\]. The average share of energy intake from meat consumption increased from 5.1% to 14.2% in the nation during 1970-1993 \[[@b19-crt-2014-001]\]. This "modified (or westernized)" dietary pattern became more robust among younger and metropolitan residents with more education and higher income in the nation during 1998-2005 \[[@b20-crt-2014-001]\]. Korea's convergence with other developed nations has been apparent in medical technology as well, particularly in selective, customized cancer treatment \[[@b21-crt-2014-001]\]. With the establishment of the National Cancer Center in 2000 and the legislation of the Cancer Control Act in 2003, the Second 10-Year Plan for Cancer Control in Korea during 2006-2015 has contributed to the rise of 5-year relative cancer survival from 53.7% during 2001-2005 to 64.1% during 2006-2010 \[[@b22-crt-2014-001]\]. These economic, demographic, behavioral, technological, and sociopolitical changes might have aided in the shift of cancer from acute to chronic in Korea.

Unlike Australia, Canada, and the United States, however, Korea has been characterized by the continued importance of stomach and liver cancers during 2000-2010 according to the results of this work. In terms of the total burden, these two cancers ranked first and second in 2000 (2,065, 2,036 million US\$), holding the same positions in 2010 (3,114, 3,046 million US\$). Indeed, a change in the pattern of economic burden for major cancers in Korea has been much more dramatic than in other advanced nations. For example, it took 36 years in the United States for the share of mortality cost to hit 51% (in 2008) from 73% (in 1972). However, the length of that period was just 10 years for Korea, given that the statistic for the nation started at 71% in 2000 and arrived at 51% in 2010. These results suggest that the economic burden of cancer in Korea follows the pattern of other advanced nations in general but also registers some unique characteristics affected by its distinctive epidemiological and sociocultural contexts, e.g., higher sodium intake (regarding stomach cancer), higher infection of hepatitis B virus (regarding liver cancer), over-diagnosis of thyroid cancer, and sudden advent of an aging society (regarding direct/morbidity cost) \[[@b14-crt-2014-001],[@b17-crt-2014-001]\]. With such a rapidly aging population, Korea's average annual rate of economic growth, which was 9.5% during 2000-2010 \[[@b17-crt-2014-001]\], might drop to 4.1% during 2011-2020 and decrease further to 2.8% during 2021-2030 \[[@b23-crt-2014-001]\]. Given these dramatic transitions, two recommendations can be made for cancer control in Korea. First, greater focus on primary prevention, including sodium-controlled diet and hepatitis B vaccination, is needed in Korea. When economic resources are limited, primary prevention is the most costeffective strategy for reducing cancer burden, and this is particularly true for a nation like Korea, where gastrointestinal cancer is dominant with widespread bacterial infection \[[@b24-crt-2014-001]\]. Second, a more consistent and integrative system of cost-effective analysis (CEA) on cancer screening and treatment is needed in Korea. At this time, only a quarter of new screening/treatment technologies are covered by health insurance in Korea, largely because its CEA system is neither consistent nor integrative enough for timely and appropriate evaluation. More evidence might be helpful in reducing cancer burden in Korea. The findings of this study might provide good lessons and important policy implications for all nations striving for rapid economic growth and experiencing sudden sociocultural transformations.

4. Limitations of this study
----------------------------

For the calculation of the expected value of the future income or women's opportunity cost for housework during potential years of life lost from a base year, it was presumed that (1) the participation rate for economic activity and the employment rate (varying by gender and age group in a given year) stay the same in the future as in the base year and (2) the women's non-participation rate for economic activity (varying by age group in a given year) remains the same in the future as in the base year. Modifying these assumptions might improve the accuracy of estimating mortality cost. Also, projecting Korea's cancer burden over 2010-2030 might provide additional insight into existing literature on cancer burden. Indeed, comparative analysis of Korea and other nations might contribute to more systematic examination of cancer burden. In addition, the extension of this study into all main diseases in Korea is expected to further the boundary of knowledge on disease burden. Despite these limitations, this research constructs rich data and presents a rare comprehensive examination of cancer burden in Korea, a nation with the most rapid demographic, socioeconomic, behavioral, and technological transformations in the past four decades.

Conclusion
==========

Incorporation of distinctive epidemiological, sociocultural contexts into Korea's cancer control program, with greater emphasis on primary prevention such as sodium-controlled diet and hepatitis B vaccination, may be needed.
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###### 

Cancer burden: components, formulas, and data sources

  Component/Formula                                                                                                                              Data source
  ---------------------------- ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------
  Direct cost                                                                                                                                    
   Medical, covered (MC)                                                                                                                         
    i/j                        Gender (M, F)/age group index                                                                                     
    MC~1ij~                    MC hospitalization                                                                                                \[[@b15-crt-2014-001]\]
    MC~2ij~                    MC outpatient visit                                                                                               \[[@b15-crt-2014-001]\]
    Formula                    ∑ij (MC~1ij~+MC~2ij~)                                                                                             \[[@b12-crt-2014-001]\]
   Medical, Uncovered (MU)                                                                                                                       
    R~1~                       MU~1~/(MC~1~+MU~1~) hospitalization                                                                               \[[@b16-crt-2014-001]\]
    R~2~                       MU~2~/(MC~2~+MU~2~) outpatient visit                                                                              \[[@b16-crt-2014-001]\]
    MU~1ij~                    MC~1ij~^\*^\[R~1~/(1--R~1~)\]                                                                                     \[[@b15-crt-2014-001],[@b16-crt-2014-001]\]
    MU~2ij~                    MC~2ij~^\*^\[R~2~/(1--R~2~)\]                                                                                     \[[@b15-crt-2014-001],[@b16-crt-2014-001]\]
    Formula                    ∑~ij~(MU~1ij~+MU~2ij~)                                                                                            \[[@b13-crt-2014-001]\]
   Transportation                                                                                                                                
    T~ij~                      Transportation cost per visit day                                                                                 \$4.9 in 2002 \[[@b12-crt-2014-001]\]
    D~2ij~                     Outpatient visit days                                                                                             \[[@b15-crt-2014-001]\]
    2                          Factor from family member's visit                                                                                 \[[@b12-crt-2014-001]\]
    Formula                    ∑~ij~ T~ij~^\*^D~2ij~^\*^2                                                                                        Inflation \[[@b15-crt-2014-001],[@b17-crt-2014-001]\]
   Caregiver                                                                                                                                     
    C~1ij~                     Caregiver cost per inpatient day                                                                                  \$50 in 2002 \[[@b12-crt-2014-001]\]
    D~1ij~                     Inpatient days                                                                                                    \[[@b15-crt-2014-001]\]
    C~2ij~                     Caregiver cost per visit hour                                                                                     \$9.3 in 2002 \[[@b12-crt-2014-001]\]
    4                          Hours per outpatient visit                                                                                        \[[@b12-crt-2014-001]\]
    D~2ij~                     Outpatient visit days                                                                                             \[[@b15-crt-2014-001]\]
    Formula                    ∑~ij~(C~1ij~^\*^D~1ij~)+∑~ij~(C~2ij~^\*^4^\*^D~2ij~)                                                              Inflation \[[@b12-crt-2014-001],[@b17-crt-2014-001]\]
   Alternative medicine (AM)                                                                                                                     
    AM~ij~                     AM cost per patient                                                                                               \$1,150 in 2002 \[[@b12-crt-2014-001]\]
    P~ij~                      Patients                                                                                                          \[[@b15-crt-2014-001]\]
    Formula                    ∑~ij~ AM~ij~^\*^P~ij~                                                                                             Inflation \[[@b12-crt-2014-001],[@b17-crt-2014-001]\]
  Indirect cost                                                                                                                                  
   Morbidity                                                                                                                                     
    W~ij~                      Yearly wage (W~Fj~: for women)                                                                                    \[[@b17-crt-2014-001]\]
    P~ij~                      Patients                                                                                                          \[[@b15-crt-2014-001]\]
    A~ij~                      Participation rate for economic activity                                                                          \[[@b17-crt-2014-001]\]
    E~ij~                      Employment rate                                                                                                   \[[@b17-crt-2014-001]\]
    L~1~                       Patient's job loss rate                                                                                           0.51 \[[@b13-crt-2014-001]\]
    H                          Participation rate for housework                                                                                  0.67 \[[@b13-crt-2014-001]\]
    L~2~                       Patient's housework loss rate                                                                                     86.5/365.0 days \[[@b13-crt-2014-001]\]
    Formula                    ∑~ij~W~ij~^\*^P~ij~^\*^A~ij~^\*^E~ij~^\*^L~1~+∑j W~Fj~^\*^P~Fj~^\*^(1--A~Fj~)^\*^H^\*^L~2~                        \[[@b13-crt-2014-001]\]
   Mortality                                                                                                                                     
    k                          Year Index (t+1, t+2,... , t+70 - j)                                                                              \-
    M~ij~                      Mortalities at year t                                                                                             \[[@b17-crt-2014-001]\]
    w                          Average annual wage growth rate                                                                                   0.08 for 2000-2010 \[[@b17-crt-2014-001]\]
    W~ijk~                     W~ij~ at year t+k \[or W~ij~^\*^(1+w)^k^\]                                                                        \[[@b17-crt-2014-001]\]
    A~ijk~                     A~ij~ at year t+k \[or A~i,j~+k\]                                                                                 \[[@b17-crt-2014-001]\]
    E~ijk~                     E~ij~ at year t+k \[or E~i,j~+k\]                                                                                 \[[@b17-crt-2014-001]\]
    H                          H at year t+k \[or H\]                                                                                            0.67 \[[@b13-crt-2014-001]\]
    r                          Discount rate                                                                                                     0.03 \[[@b13-crt-2014-001]\]
    Formula                    ∑~ij~M~ij~{∑k \[(W~ijk~^\*^A~ijk~^\*^E~ijk~)/(1+r)^k^\]}+∑~j~ MF~j~{∑k \[W~Fjk~^\*^(1--A~Fjk~)^\*^H/(1+r)^k^\]}   \[[@b13-crt-2014-001]\]

###### 

Number of cancer patients in Korea by cancer site and gender in 2000 and 2010

  Cancer type      ICD-10 code   Men       Women     Total     Rank for total                            
  ---------------- ------------- --------- --------- --------- ---------------- --------- --------- ---- ----
  Thyroid          C73           14,382    59,191    31,237    137,299          45,619    196,490   5    1
  Stomach          C16           59,491    87,846    32,430    47,156           91,921    135,002   1    2
  Colorectum       C18-C21       32,420    65,443    27,001    51,922           59,421    117,365   2    3
  Breast           C50           600       996       42,005    96,511           42,605    97,507    6    4
  Lung             C33-34        37,243    38,226    15,659    16,071           52,902    54,297    4    5
  Liver            C22           41,348    38,657    15,813    15,151           57,161    53,808    3    6
  Prostate         C61           9,881     36,105    0         0                9,881     36,105    14   7
  Kidney           C64           6,465     18,412    3,390     10,170           9,855     28,582    15   8
  Uterine cervix   C53           0         0         27,990    28,021           27,990    28,021    7    9
  Bladder          C67           9,089     16,075    2,585     5,011            11,674    21,086    12   10
  NHL              C82-C85       5,570     4,944     11,691    11,627           17,261    16,571    8    11
  Ovary            C56           0         0         16,403    14,542           16,403    14,542    9    12
  Mouth            C00-C14       9,224     7,647     6,515     5,559            15,739    13,206    10   13
  Brain            C69-C72       5,690     6,333     5,611     6,088            11,301    12,421    13   14
  Leukemia         C91-C95       4,516     6,500     4,127     5,904            8,643     12,404    17   15
  Pancreas         C25           5,700     6,001     4,139     4,687            9,839     10,688    16   16
  Uterus           C54-C55       0         0         4,209     9,989            4,209     9,989     21   17
  Skin             C43-C44       2,262     4,800     2,523     5,053            4,785     9,853     20   18
  Esophagus        C15           5,979     5,990     1,092     1,067            7,071     7,057     18   19
  Larynx           C32           5,334     6,192     851       740              6,185     6,932     19   20
  MM               C90           1,522     2,390     1,258     1,965            2,780     4,355     22   21
  Gallbladder      C23-C24       7,832     1,605     6,602     1,402            14,434    3,007     11   22
  Testis           C60,62,63     1,722     1,747     0         0                1,722     1,747     23   23
  HL               C81           552       475       925       956              1,477     1,431     24   24
  Others                         7,372     7,958     6,152     6,923            13,524    14,881         
  Total                          274,194   423,534   270,208   483,813          544,402   907,347        

Source: Korea Health Insurance Corporation \[[@b15-crt-2014-001]\]. ICD-10, International Classification of Diseases 10th revision; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; HL, Hodgkin lymphoma.

###### 

Number of cancer mortalities in Korea by cancer site and gender in 2000 and 2010

  Cancer type      ICD-10 code   Men      Women    Total    Rank for total                          
  ---------------- ------------- -------- -------- -------- ---------------- -------- -------- ---- ----
  Lung             C33-C34       8,575    11,411   2,965    4,204            11,540   15,615   1    1
  Liver            C22           7,697    8,350    2,343    2,855            10,040   11,205   3    2
  Stomach          C16           7,434    6,512    4,069    3,520            11,503   10,032   2    3
  Colorectum       C18-C21       2,239    4,350    1,962    3,351            4,201    7,701    4    4
  Pancreas         C25           1546     2,323    1,162    1,983            2,708    4,306    5    5
  Gallbladder      C23-C24       1,355    1,758    1,289    1,744            2,644    3,502    6    6
  Breast           C50           21       10       1,148    1,858            1,169    1,868    9    7
  Leukemia         C91-C95       789      922      574      696              1,363    1,618    8    8
  NHL              C82-C85       553      807      316      623              869      1,430    12   9
  Esophagus        C15           1,351    1,254    149      98               1,500    1,352    7    10
  Prostate         C61           545      1,328    0        0                545      1,328    18   11
  Brain            C69-C72       534      652      464      543              998      1,195    11   12
  Bladder          C67           588      822      182      278              770      1,100    13   13
  Mouth            C00-C14       661      742      393      221              1,054    963      10   14
  Uterine cervix   C53           0        0        726      956              726      956      15   15
  Ovary            C56           0        0        561      895              561      895      17   16
  Kidney           C64           337      562      175      235              512      797      19   17
  MM               C90           169      399      118      364              287      763      21   18
  Larynx           C32           651      383      109      33               760      416      14   19
  Skin             C43-C44       168      177      132      206              300      383      20   20
  Thyroid          C73           73       94       193      262              266      356      22   21
  Uterus           C54-C55       0        0        584      316              584      316      16   22
  HL               C81           156      46       91       35               247      81       23   23
  Testis           C60,62,63     38       20       0        0                38       20       24   24
  Total                          35,480   42,922   19,705   25,276           55,185   68,198        

Source: Korea Health Insurance Corporation \[[@b17-crt-2014-001]\]. ICD-10, International Classification of Diseases 10th revision; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; HL, Hodgkin lymphoma.

###### 

Economic burden in Korea by cancer site, gender in 2000 and 2010 (million US\$)

  Cancer type      ICD-10 code    Men (M)         Women (W)      Total (T)      Rank for total \[M/W\]                                                 
  ---------------- -------------- --------------- -------------- -------------- ------------------------ --------------- -------------- -------------- --------------
  Liver            C22            1,744 (0.80)    2,638 (0.74)   322 (0.75)     477 (0.62)               2,065 (0.79)    3,114 (0.72)   1 \[1/5\]      1 \[1/7\]
  Stomach          C16            1,332 (0.67)    2,090 (0.51)   704 (0.78)     956 (0.61)               2,036 (0.71)    3,046 (0.54)   2 \[2/1\]      2 \[2/3\]
  Colorectum       C18-C21        525 (0.55)      1,420 (0.42)   312 (0.57)     790 (0.41)               837 (0.55)      2,210 (0.41)   5 \[5/6\]      3 \[4/4\]
  Lung             C33-C34        881 (0.69)      1,476 (0.57)   322 (0.76)     512 (0.63)               1,202 (0.71)    1,988 (0.58)   4 \[3/4\]      4 \[3/5\]
  Thyroid          C73            110 (0.08)      707 (0.02)     147 (0.07)     1,017 (0.01)             257 (0.07)      1,724 (0.01)   11 \[13/10\]   5 \[6/2\]
  Breast           C50            11 (0.68)       11 (0.05)      518 (0.57)     1,648 (0.38)             529 (0.57)      1,659 (0.37)   7 \[21/2\]     6 \[21/1\]
  Leukemia         C91-C95        790 (0.93)      965 (0.80)     433 (0.91)     521 (0.71)               1,223 (0.92)    1,475 (0.77)   3 \[4/3\]      7 \[5/6\]
  Brain            C69-C72        395 (0.88)      678 (0.84)     303 (0.89)     324 (0.78)               698 (0.89)      1,002 (0.82)   6 \[6/7\]      8 \[7/10\]
  NHL              C82-C85        260 (0.81)      416 (0.57)     133 (0.64)     236 (0.59)               394 (0.75)      649 (0.58)     8 \[7/11\]     9 \[9/11\]
  Pancreas         C25            210 (0.79)      420 (0.76)     95 (0.75)      198 (0.69)               304 (0.78)      618 (0.73)     9 \[8/13\]     10 \[8/12\]
  Uterine cervix   C53            0 (0.00)        0 (0.00)       257 (0.49)     448 (0.47)               257 (0.49)      448 (0.47)     12 \[22/8\]    11 \[22/8\]
  Kidney           C64            116 (0.62)      303 (0.32)     57 (0.75)      98 (0.30)                173 (0.67)      402 (0.31)     15 \[12/15\]   12 \[10/15\]
  Ovary            C56            0 (0.00)        0 (0.00)       179 (0.51)     364 (0.53)               179 (0.51)      364 (0.53)     14 \[22/9\]    13 \[22/9\]
  Mouth            C00-C14        134 (0.55)      253 (0.52)     48 (0.50)      85 (0.52)                182 (0.53)      338 (0.52)     13 \[11/16\]   14 \[12/16\]
  Prostate         C61            55 (0.21)       295 (0.11)     0 (0.00)       0 (0.00)                 55 (0.21)       295 (0.11)     22 \[16/23\]   15 \[11/23\]
  Gallbladder      C23-C24        173 (0.67)      164 (0.84)     121 (0.71)     106 (0.84)               293 (0.69)      270 (0.84)     10 \[9/12\]    16 \[15/14\]
  Bladder          C67            81 (0.33)       182 (0.21)     16 (0.39)      39 (0.22)                98 (0.34)       220 (0.21)     17 \[14/20\]   17 \[14/19\]
  Esophagus        C15            142 (0.68)      183 (0.49)     17 (0.75)      15 (0.40)                159 (0.69)      198 (0.48)     16 \[10/19\]   18 \[13/21\]
  MM               C90            33 (0.61)       102 (0.48)     16 (0.49)      59 (0.35)                49 (0.57)       161 (0.43)     23 \[19/21\]   19 \[16/18\]
  Skin             C43-C44        46 (0.72)       81 (0.47)      22 (0.59)      66 (0.52)                68 (0.68)       147 (0.49)     21 \[18/18\]   20 \[18/17\]
  Uterus           C54-C55        0 (0.00)        0 (0.00)       91 (0.79)      140 (0.39)               91 (0.79)       140 (0.39)     18 \[22/14\]   21 \[22/13\]
  Larynx           C32            76 (0.57)       86 (0.31)      6 (0.48)       5 (0.14)                 82 (0.57)       91 (0.30)      19 \[15/22\]   22 \[17/22\]
  HL               C81            49 (0.91)       31 (0.59)      28 (0.88)      20 (0.68)                77 (0.90)       52 (0.62)      20 \[17/17\]   23 \[20/20\]
  Testis           C60,62,63      31 (0.68)       42 (0.54)      0 (0.00)       0 (0.00)                 31 (0.68)       42 (0.54)      24 \[20/23\]   24 \[19/23\]
  Others                          52 (0.00)       117 (0.00)     30 (0.00)      75 (0.00)                82 (0.00)       191 (0.00)                    
  Total            7,247 (0.72)   12,659 (0.56)   4,178 (0.68)   8,198 (0.46)   11,424 (0.71)            20,844 (0.52)                                 

Values in rounded parentheses are presented as share of mortality cost. ICD-10, International Classification of Diseases 10th revision; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; HL, Hodgkin lymphoma.

###### 

Economic burden in Korea by cancer site, age group in 2000 and 2010 (thousand US\$)

  Cancer type     ICD-10 code   0-14 yr (A)   15-69 yr (B)   ≥ 70 yr (C)   Rank for A/B/C                                    
  --------------- ------------- ------------- -------------- ------------- ---------------- --------- ----------- ---------- ----------
  Liver           C22           43,776        23,809         1,993,174     2,960,679        28,418    129,555     5/1/4      4/1/4
  Stomach         C16           3,603         46             1,976,338     2,797,811        56,015    247,969     14/2/1     18/2/3
  Colorectum      C18-C21       10295         37             784,502       1,923,877        42,367    286,032     8/4/3      19/3/1
  Lung            C33-C34       20,177        64             1,128,019     1,734,244        54,284    253,344     7/3/2      15/4/2
  Thyroid         C73           3,524         7,071          240,046       1,639,136        13,497    77,580      15/12/6    8/5/6
  Breast          C50           43            4,319          524,637       1,614,472        4,231     40,564      21/6/15    11/6/10
  Leukemia        C91-C95       577,293       466,899        641,730       981,122          4,081     27,152      1/5/16     01/7/13
  Brain           C69-C72       343,198       366,666        350,613       617,273          3,920     18,510      2/7/17     2/8/17
  Pancreas        C25           2,780         64             291,896       570,309          9,709     47,922      16/9/8     16/9/8
  NHL             C82-C85       92,814        61,488         295,933       547,329          4,911     40,612      3/8/14     3/10/9
  Uterinecervix   C53           6             74             251,202       425,395          5,829     22,199      23/11/13   14/11/15
  Kidney          C64           49,065        14,517         117,672       353,401          6,231     33,783      4/16/12    5/12/11
  Ovary           C56           492           5,002          175,717       344,064          3,083     14,856      19/13/19   10/13/20
  Mouth           C00-C14       584           786            174,734       312,946          6,969     23,956      17/14/10   12/14/14
  Gallbladder     C23-C24       4,423         11             271,831       261,641          17,123    8,117       10/10/5    21/15/21
  Prostate        C61           26            55             42,270        173,096          12,926    122,017     22/22/7    17/16/05
  Esophagus       C15           4,374         0              148,564       167,247          6,510     30,273      11/15/11   23/17/12
  Bladder         C67           86            32             90,383        166,394          7,061     54,070      20/17/9    20/18/07
  MM              C90           497           592            46,920        140,699          2,079     19,883      18/21/21   13/19/16
  Uterus          C54-C55       4             0              90,252        134,039          733       5,612       24/18/22   24/20/22
  Skin            C43-C44       3,981         5,820          61,862        123,175          2,581     18,464      12/20/20   9/21/18
  Larynx          C32           3,731         5              75,002        75,495           3,728     15,983      13/19/18   22/22/19
  HL              C81           35,108        7,830          42,083        42,570           287       1,307       6/23/24    7/23/23
  Testis          C60,62,63     5,264         8,877          25,180        32,105           433       846         9/24/23    6/24/24
  Others                        5,481         12,979         71,531        157,980          4,656     20,191                 
  Total                         1,210,624     987,043        9,912,090     18,296,498       301,665   1,560,796              

ICD-10, International Classification of Diseases 10th revision; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; HL, Hodgkin lymphoma.

###### 

Cost components and their shares in total cost of cancer in Korea during 2000-2010 (million US\$, %)

                                         Year                                                                                                  
  -------------------------------------- --------- --------- --------- --------- --------- --------- --------- ----------- --------- --------- -----------
  Direct cost (million US\$)             1,892     1,948     2,187     2,375     2,689     3,258     4,238     5,047       5,316     5,314     6,252
  Share in total cost (%)                16.6      18.3      18.5      18.4      19.3      19.8      21.5      22.5        26.2      29.1      30.0
   Medical, covered (million US\$)       635       663       740       879       1,021     1,355     1,355     2,380       2,572     2,512     3,059
    Share in total cost (%)              5.6       6.2       6.2       6.8       7.3       8.2       8.2       10.6        12.7      13.8      14.7
   Medical, uncovered (million US\$)     331       349       386       452       521       480       480       609         780       863       787
    Share in total cost (%)              2.9       3.3       3.3       3.5       3.7       2.9       2.9       2.7         3.8       4.7       3.8
   Transportation (million US\$)         21        24        27        33        38        50        50        77          73        76        93
    Share in total cost (%)              0.2       0.2       0.2       0.3       0.3       0.3       0.3       0.3         0.4       0.4       0.4
   Caregiver (million US\$)              284       295       332       377       429       535       535       814         787       759       926
    Share in total cost (%)              2.5       2.8       2.8       2.9       3.1       3.3       3.3       3.6         3.9       4.2       4.4
   Alternative medicine (million US\$)   621       617       701       635       681       837       837       1,168       1,103     1,104     1,388
    Share in total cost (%)              5.4       5.8       5.9       4.9       4.9       5.1       5.1       5.2         5.4       6.1       6.7
  Indirect cost (million US\$)           9,533     8,720     9,661     10,531    11,241    13,188    13,188    17,375      14,987    12,920    14,606
  Share in total cost (%)                83.4      81.7      81.5      81.6      80.7      80.2      80.2      77.5        73.8      70.9      70.0
   Morbidity (million US\$)              1,457     1,445     1,709     1,649     1,725     2,160     2,160     3,289       3,108     3,004     3,815
    Share in total cost (%)              12.8      13.5      14.4      12.8      12.4      13.1      13.1      14.7        15.3      16.5      18.3
   Mortality (million US\$)              8,075     7,275     7,952     8,882     9,517     11,028    11,028    14,086      11,879    9,917     10,791
    Share in total cost (%)              70.7      68.2      67.1      68.8      68.3      67.1      67.1      62.8        58.5      54.4      51.7
  Total cost (million US\$)              11,424    10,668    11,848    12,906    13,931    16,445    16,445    22,422      20,302    18,234    20,858
  GDP (million US\$)                     533,309   504,586   576,132   643,633   722,973   844,855   844,855   1,049,349   930,296   834,439   1,014,944
  Direct cost/GDP (%)                    0.35      0.39      0.38      0.37      0.37      0.39      0.39      0.48        0.57      0.64      0.62
  Total burden/GDP (%)                   2.14      2.11      2.06      2.01      1.93      1.95      2.07      2.14        2.18      2.19      2.06

Source: Korea Health Insurance Corporation \[[@b17-crt-2014-001]\]. GDP, gross domestic product.
